Group 1 - The core viewpoint of the articles highlights the performance and valuation of Sanbo Neuroscience, which has a current stock price of 45.2 yuan and a rolling PE ratio of 84.92 times, significantly higher than the industry average of 46.29 times [1][2] - As of September 30, 2024, Sanbo Neuroscience has 27,403 shareholders, an increase of 2,446 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The company specializes in clinical medical services in neurology, with a focus on complex surgeries, achieving a high volume of operations, particularly in advanced neurosurgery [1] Group 2 - In the latest financial report for Q3 2024, Sanbo Neuroscience reported a revenue of 1.059 billion yuan, representing a year-on-year increase of 9.83%, and a net profit of 105 million yuan, up 42.93% year-on-year, with a gross margin of 24.97% [1] - The company ranks 37th in terms of PE ratio within the medical services industry, which has an average PE of 46.29 times and a median of 47.83 times [2]